Results 21 to 30 of about 537,211 (318)
Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms [PDF]
, 2002 Background: Severe allergic reactions during rush-specific immunotherapy (Rush-SIT) may occur in the treatment of hymenoptera sting allergy. The objective of the present study was to examine the characteristics of allergic reactions during Rush-SIT in a ...
Mingomataj, Ervin +6 more
core +1 more source
Electroporation and Immunotherapy—Unleashing the Abscopal Effect [PDF]
, 2022 SIMPLE SUMMARY: Electrochemotherapy and irreversible electroporation are primarily used for treating patients with cutaneous and subcutaneous tumors and pancreatic cancer, respectively.
Nolsoe, Christian +9 more
core +1 more source
Modulation of Endosome Function, Vesicle Trafficking and Autophagy by Human Herpesviruses
Cells, 2021 Human herpesviruses are a ubiquitous family of viruses that infect individuals of all ages and are present at a high prevalence worldwide. Herpesviruses are responsible for a broad spectrum of diseases, ranging from skin and mucosal lesions to blindness ...
Eduardo I. Tognarelli +6 more
doaj +1 more source
Clinical effectiveness of hymenoptera venom immunotherapy [PDF]
, 2013 Treatment failure during venom immunotherapy (VIT) may be associated with a variety of risk factors. Our aim was to evaluate the association of baseline serum tryptase concentration (BTC) and of other parameters with the frequency of VIT failure during ...
Scheipl, Fabian +21 more
core +1 more source
Assessing the Future of Solid Tumor Immunotherapy [PDF]
, 2022 With the advent of cancer immunotherapy, there has been a major improvement in patient’s quality of life and survival. The growth of cancer immunotherapy has dramatically changed our understanding of the basics of cancer biology and has altered the
Kyle P. O’Connell +4 more
core +1 more source
Metabolic Barriers to Glioblastoma Immunotherapy [PDF]
, 2023 Glioblastoma (GBM) is the most common primary brain tumor with a poor prognosis with the current standard of care treatment. To address the need for novel therapeutic options in GBM, immunotherapies which target cancer cells through stimulating an anti ...
Jun Y. Oh +3 more
core +1 more source
Nature Communications, 2022 Plasma B cells (PC) are a potential source for protein replacement as they could be engineered to secrete protein other than antibody. Here the authors engineer B cells to express exogenous proteins and demonstrate that these cells can persist long term ...
Rene Yu-Hong Cheng +11 more
doaj +1 more source
Escape from immunotherapy: possible mechanisms that influence tumor regression/progression [PDF]
, 2004 Tumor escape is one major obstacle that has to be addressed prior to designing and delivering successful immunotherapy. There is compelling evidence to support the notion that immunogenic tumors, in murine models and cancer patients, can be rejected by ...
Ahmad, M, Ali, SA, Rees, RC
core +1 more source
Asthma immunotherapy and treatment approaches with mesenchymal stem cells [PDF]
, 2020 Asthma is a chronic inflammatory disease of the airways where exaggerated T helper 2 immune responses and inflammatory mediators play a role. Current asthma treatment options can effectively suppress symptoms and control the inflammatory process; however,
AKKOÇ, TUNÇ
core +1 more source